Breaking News, Collaborations & Alliances

BioNTech & Autolus Partner to Advance CAR-T Therapies, Boost Pipeline Efficiency

New collaboration is aimed at advancing both companies’ autologous CAR-T programs towards commercialization, pending regulatory authorizations.

Author Image

By: Charlie Sternberg

Associate Editor

BioNTech SE, a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, and Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, have announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs towards commercialization, pending regulatory authorizations.   In connection with the strategic collaboration, the companies entered into a license...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters